Sherbrooke Park Advisers LLC Nurix Therapeutics, Inc. Transaction History
Sherbrooke Park Advisers LLC
- $215 Billion
- Q3 2025
A detailed history of Sherbrooke Park Advisers LLC transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Sherbrooke Park Advisers LLC holds 10,817 shares of NRIX stock, worth $138,457. This represents 0.05% of its overall portfolio holdings.
Number of Shares
10,817Holding current value
$138,457% of portfolio
0.05%Shares
1 transactions
Others Institutions Holding NRIX
# of Institutions
186Shares Held
77.4MCall Options Held
99.8KPut Options Held
11.3K-
Black Rock Inc. New York, NY6.82MShares$87.3 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT6.06MShares$77.5 Million1.77% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.49MShares$57.5 Million0.0% of portfolio
-
Baker Bros. Advisors LP New York, NY3.88MShares$49.7 Million0.29% of portfolio
-
Commodore Capital LP New York, NY3.78MShares$48.4 Million2.23% of portfolio
About Nurix Therapeutics, Inc.
- Ticker NRIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,147,800
- Market Cap $603M
- Description
- Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...